Estimating Breast Cancer Survival by Molecular Subtype in the Absence of Screening and Adjuvant Treatment.

ABSTRACT:

Background

As molecular subtyping of breast cancer influences clinical management, the evaluation of screening and adjuvant treatment interventions at the population level needs to account for molecular subtyping. Performing such analyses are challenging because molecular subtype-specific, long-term outcomes are not readily accessible; these markers were not historically recorded in tumor registries. We present a modeling approach to estimate historical survival outcomes by estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2) status.

Method

Our approach leverages a simulation model of breast cancer outcomes and integrates data from two sources: the Surveillance Epidemiology and End Results (SEER) databases and the Breast Cancer Surveillance Consortium (

SUBMITTER: Munoz DF 

PROVIDER: S-EPMC6635303 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature